For more than two decades, our innovations in rare disease medicines have positively transformed the trajectory of the patient journey for people living with certain rare haematological diseases-establishing and advancing the treatment landscape for a rare, chronic, progressive and potentially life-threatening blood disease driven by dysregulation of the complement system. We are committed to following the science, improving the understanding of rare haematological diseases and enhancing the patient and caregiver journey.